SCM
CTNM

Sterling Capital Management’s Contineum Therapeutics CTNM Stock Holding History

Sterling Capital Management’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.88K Buy
+542
New +$7.11K ﹤0.01% 2288
2025
Q2 		– Sell
-78
Closed -$544 – 3427
2025
Q1 		$544 Hold
78
– – ﹤0.01% 2947
2024
Q4 		$1.14K Buy
78
+65
+500% +$1.03K ﹤0.01% 2914
2024
Q3 		$249 Buy
+13
New +$249 ﹤0.01% 3080

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Sterling Capital Management's CTNM Position: Q2 2026 in Review

Sterling Capital Management opened a new position in Contineum Therapeutics (CTNM) in Q2 2026: 542 shares worth $8.88K. The stake represents ﹤0.01% of the portfolio and ranks #2288 among its holdings. This is a return to the name: Sterling Capital Management previously reported a position in CTNM as recently as Q1 2025.

Sterling Capital Management first reported a position in CTNM in Q3 2024 and has held it in 4 quarters since. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • Sterling Capital Management held 542 shares of Contineum Therapeutics worth $8.88K as of Q2 2026.
  • Contineum Therapeutics was a new Sterling Capital Management position in Q2 2026.
  • Contineum Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2288 holding.
  • Sterling Capital Management first reported a position in Contineum Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.